Kornimate/medical-research-clean huggingface dataset:
eye-sync concussion classification study

Conditions: Concussion, Mild; Concussion; Eye; Concussion, Brain; Concussion, Severe; Brain Injuries; Concussion, Cerebral

Summary: the purpose of this study is to determine the sensitivity and specificity of an aid in assessment of concussion based on eye-tracking, in comparison to a clinical reference standard appropriate for sport-related concussion evaluation.


Eligibility criteria:
inclusion criteria: * men and women actively engaged in competitive athletics * eye tracking measurements and scat5 evaluations are collected within 3-day window * eye tracking measurements and scat5 evaluations are collected within 3 days of injury exclusion criteria: * prior enrollment (subjects may only enroll once) * poor eye tracking data quality * subjects without reported injury detailing alteration of consciousness (aoc) or altered mental status (ams) defined as self-report, witness report or the following responses to the scat5 sss: "difficulty remembering" ≥ 4 or "confusion" ≥ 4, or scored less than 23 on the scat5 standardized assessment of concussion (sac) or greater than 25 on the scat5 symptom severity score (sss) * eye-sync smooth pursuit standard deviation of tangential error (sdte) variance scores \< 2.0
early detection of vaping-related vascular diseases

Conditions: Vaping; Blood Vessel Injury

Summary: the purpose of this study is to determine how vaping affects blood vessels, in particular if early damage occurs in the lung vessels.


Eligibility criteria:
inclusion criteria: vapers group: 1. current electronic cigarette (ec) puff bar users defined as using ec either daily or occasionally in the past 30 days for at least 6 months, and with 5% nicotine concentration pods. 2. adults aged 18-40 years healthy group: 1. healthy never smokers, never vapers 2. adults aged 18-40 years exclusion criteria: 1. current or past smoking of tobacco cigarette (tc) or other tobacco/nicotine products (e.g., smokeless tobacco, hookah) or marijuana will be excluded from the study. 2. subjects with self-reported history of chronic health problems including asthma, chronic obstructive pulmonary disease (copd), morbid obesity (bmi\>40 kg/m2), hypertension or diabetes 3. pregnant or breastfeeding women
the swedish prison program is an intervention prevention program targeting injecting drug users risk behaviours and infectious diseases

Conditions: Having Ever Injected Drugs

Summary: the purpose of the swedish prison program which started back in 1987 and up until 2009 was called "the social medicine remand prison project" is to target injecting drug users (idu) with primary and secondary health interventions with regards to injecting and sexual risk behaviours and infectious diseases such as hepatitis c and b, hiv and sexually transmitted infections (sti). the overall aim is to assess the effect of different prevention efforts on hiv/hcv risk behaviour and disease outcome among idus over time.

risk behaviour for idu is sexual risk taking, i.e., sex without a condom, buying or selling sex and injection risk taking, i.e., sharing needle, syringe or paraphernalia.

Eligibility criteria:
inclusion criteria: * defined as an injecting drug user, in the prison and probation service and agree to anonymously participate exclusion criteria: * being defined as a non-drug user, non-injecting drug user
integration of intraoperative neuromonitoring into decompression surgery

Conditions: Nerve Entrapments; Pelvic Pain

Summary: to describe a novel technique by integrating the intraoperative neurophysiological monitoring (ionm) into laparoscopy to protect pelvic nerves by continuously monitoring when they are at risk during surgery.

we integrated intraoperative neuromonitoring system into laparoscopic lumbosacral plexus nerve decompression surgery and simultaneusly recorded nerve roots from lumbar 5 to sacral 4 during the operation. diseases that cause pelvic nerve compression such as abnormal vascular conflict, aberrant priformis muscle, and endometriosis have settled in hard-to-reach deep areas of the pelvis. sacral and sciatic nerves might be damaged when performing decompression surgery in these deep pelvic areas. we described a novel technique by integrating the intraoperative neurophysiological monitoring (ionm) into laparoscopy to protect pelvic nerves by continuously monitoring when they are at risk during surgery.

Eligibility criteria:
inclusion criteria: * patients with symptoms of chronic pelvic pain , dyspareunia, dysmenorrhea and severe, burning sharp pain on the lower extremity dermatomes, which had been present for at least one year were included. exclusion criteria: * patients who underwent laparoscopic decompression surgery but did not give informed consent were not included in the study.
reactions to contrast media (cm) administered at the time of the endoscopic retrograde cholangiopancreatography (ercp)

Conditions: Contrast Allergies

Summary: the aim of this study is to prospectively document the incidence of cm adverse reactions at the time of ercp and to determine whether various perceived risk factors are predictive of adverse reaction. adverse reactions to iodine containing contrast media (cm) have been described after endoscopic retrograde cholangiopancreaticography (ercp) but have been difficult to study due to their extremely low incidence. adverse reactions can be classified by severity (mild, moderate or severe) or underlying mechanism (idiosyncratic versus nonidiosyncratic). nonidiosyncratic reactions are related to the dose and osmolality of the cm; these are not observed during ercp due to the relative small amount of systemic absorption of cm. idiosyncratic reactions on the other hand are not dose-dependent and generally occur shortly after administration of cm. premedication with corticosteroids, h1/h2 -blockers and the use of low osmolality cm is beneficial in preventing nonidiosyncratic reactions during intravascular administration. however their role in during ercp is unclear as cm is not injected into the intravascular space. currently there are no formal recommendations and clinical practice varies considerably. the general purpose of this study is to determine the incidence of cm reactions during ercp and to determine whether various risk factors are predictive of idiosyncratic reactions. based on these results, we hope to develop guidelines for the use of prophylaxis to prevent cm reactions in ercp.


Eligibility criteria:
inclusion criteria: 1. age 18 years or older. 2. scheduled to undergo ercp at the university of florida, gainesville, fl 3. history of prior reaction to iv cm and/or shellfish allergy 4. subject must be able to give informed consent exclusion criteria: 1. any contraindication to performing ercp. 2. participation in another research protocol that could interfere or influence the outcomes measures of the present study. 3. the subject is unable/unwilling to give informed consent.
systematic evaluation of patients treated with stroke devices for acute ischemic stroke (stratis) registry

Conditions: Ischemic Stroke

Summary: the purpose of this registry is to assess clinical outcomes, and different factors that may affect these clinical outcomes such as systems of care, associated with the use of covidien market-released neurothrombectomy devices intended to restore blood flow in patients experiencing acute ischemic stroke due to large intracranial vessel occlusion.

this is a prospective, multi-center, non-randomized, observational registry of acute ischemic stroke patients that have or will undergo treatment with the use of a covidien market-released neurothrombectomy device (as the initial device used to remove the thrombus) within 8 hours of stroke symptom onset, at the discretion of the investigator and independent of participation in this registry. this registry may enroll up to 1000 patients.

Eligibility criteria:
inclusion criteria: * patient or patient's legally authorized representative has given informed consent according to good clinical practices (gcp) and/or irb and/or local or institutional policies. * patient has experienced an acute ischemic stroke due to large intracranial vessel occlusion (with associated symptoms) and has been or will be treated with a covidien market-released neurothrombectomy device, as the initial device used to remove the thrombus. * treatment within 8 hours of stroke onset. * pre-stroke modified rankin scale (mrs) score ≤ 1 (immediately) prior to stroke onset. * pre-treatment national institutes of health stroke scale (nihss) ≥ 8 and ≤ 30. exclusion criteria: * concurrent participation in a multicenter randomized study.
oncoliq: early breast cancer detection based on liquid biopsies and micrornas

Conditions: Breast Cancer Female; Breast Cancer; Breast Carcinoma

Summary: oncoliq is a novel early breast cancer detection test based on liquid biopsies and micrornas. this innovative test aims to improve the accuracy of cancer detection, thereby reducing patient mortality and healthcare costs. to develop this test, the discovery and validation phases have been completed. in addition, machine learning and ai were used to determine the algorithm for breast cancer detection. the overall objective of this protocol is to implement a pilot test to enroll 1,000 women without a previous cancer diagnosis who are attending their annual medical check-up. to achieve this, we will develop the following specific objectives: enroll women over age 35 who attend the gynecological annual check-up. test the plasma of the enrolled volunteers for specific mirna biomarkers using rt-qpcr. perform an analysis based on artificial intelligence techniques in collaboration with imago systems (usa) on mammogram images. compare the results obtained from the clinical check-up (birad from mammogram), imago systems and rt-qpcr (oncoliq breast test). conduct a 5-year follow-up on volunteers with pathological results from oncoliq breast test. participants who meet the inclusion and exclusion criteria and agree to take part in the protocol will be required to sign both pages of the informed consent form and complete the annex and survey. subsequently, a small blood sample of 3-5 ml will be drawn via venipuncture.


Eligibility criteria:
inclusion criteria: * patients over 35 years old who visit the gynecological clinic for their annual mammographic check-up exclusion criteria: * personal history of cancer

Keywords: early diagnosis early detection cancer breast cancer mirnas liquid biopsies pilot study pilot test liquid biopsy oncoliq machine learning ai rt-qpcr
the predictive value of immune cell in locally advanced cervical cancer

Conditions: Locally Advanced Cervical Carcinoma; Concurrent Chemoradiotherapy; Immunotherapy

Summary: to explore the predictive value of immune cells by single-cell sequencing on the outcome of locally advanced cervical cancer treated by concurrent chemoradiotherapy followed by pd-1 inhibitor

concurrent chemoradiotherapy is the standard treatment for patients with locally advanced cervical cancer, but the treatment failure rate is up to 40% in previous studies. immunotherapy using pd-1 inhibitor showed an objective response rate of 12-50% in studies, and pembrolizumab was approved by the us food and drug administration for patients with advanced pd-l1-positive cervical cancer who experienced progression during or after chemotherapy. and according to keynote-a18, the addition of pd-1 inhibitor pembrolizumab to the current concurrent chemoradiotherapy improved the pfs of such group of patients. but the detailed change of immune cells (tumor microenvironment and pbmc) during treatment is unknown, and studies on the relationship between immune cells and treatment-related side effect and efficiency is also in need.

Eligibility criteria:
inclusion criteria: 1. age between 18 and 75; 2. untreated patients with pathologically proven locally advanced cervical cancer; 3. eastern cooperative oncology group (ecog) performance status of 0-1 4. adequate hematological, renal and hepatic functions: 4.1 hemoglobin \> 8.0 g/dl 4.2 neutrophils \> 2000 cells/μl; leukocytes \> 4 × 109/l 4.3 platelets \> 100 × 109/lg. 4.4 serum urea nitrogen (bun) ≤ 1.5 × upper normal limit (unl) 4.5 serum creatinine (cr) ≤ 1.5 × upper normal limit (unl) 4.6 serum alt/ast ≤ 2.5× unl 4.7 serum total bilirubin ≤ 1.5× unl 5. life expectancy \> 6 months 6. eligible for concurrent chemoradiotherapy assessed by principle investigator; 7. no obvious active bleeding; 8. written informed consent must be available before study registration exclusion criteria: 1. recurrent or distant metastatic disease; 2. prior malignancies (other than curable non-melanoma skin cancer) within 5 years; 3. active autoimmune diseases requiring systemic treatment or other diseases requiring long-term use of substantial amount of hormones or other immunosuppressants; 4. patients who need to receive systemic corticosteroids (dose equivalent to or higher than prednisone 10mg qd) or other immunosuppressants within 14 days before enrollment or during the study; 5. vaccination of live attenuated vaccine 30 days before enrollment, or planned vaccination of live attenuated vaccine during the study; 6. previous organ transplantation or hiv patients; 7. allergic to macromolecular proteins /monoclonal antibodies, or to any test drug component; 8. active acute or chronic viral hepatitis b or c. hepatitis b virus (hbv) dna\> 2000iu/ml or 104 copies/ml; hepatitis c virus (hcv) rna\> 103 copies/ml.
high flow nasal cannula versus high velocity nasal insufflation in covid-19

Conditions: COVID-19; Acute Respiratory Failure

Summary: to compare the outcomes of hfnc and hvni in covid-19 patients with acute respiratory failure as regard need for mechanical ventilation, changes of arterial blood gases (abg) parameters, duration of ventilatory support and delay between admission and intubation

novel clinical syndrome caused by a previously unknown coronavirus, sars-cov-2, was first identified in wuhan (china) in december 2019. despite massive efforts to contain viral transmission, a worldwide epidemic has developed from this virus. this disease is presently known as covid-19 covid-19 pandemic reached over 45 million confirmed infections and claimed the lives of more than 1.2 million people worldwide. the clinical features of covid-19 are diverse and range from asymptomatic to critical illness and death. severe and critical cases represented 14% and 5% of laboratory-confirmed covid-19 patients and need icu admission several non-invasive options exist to support covid-19 patients with mild or moderate respiratory distress and may reduce the numbers of patients requiring intubation, mechanical ventilation in some severely ill patients such as high flow nasal oxygen (hfno) high flow nasal oxygen (hfno) includes high flow nasal cannula and high velocity nasal insufflation. high flow oxygen systems provide oxygen-rich heated humidified gas to the patient's nose at flow levels sufficient to deliver a constant, precisely set high fio2. exhalation is to the open air. hfno reduces dead space, provides low levels of peep, and decreases breathing frequency and work of breathing hfnc flow rates reach up to 60 l/min, whereas hvni delivers flow rates up to 40 l/min due to differing mechanisms of delivery (4). high velocity nasal insufflation (hvni) utilizes a small-bore nasal cannula to generate higher velocities of gas delivery than hfnc which uses large bore cannula

Eligibility criteria:
inclusion criteria: * covid-19 positive by rt-pcr * age≥ 18 years * both gender * classical radiological lesions of covid-19 on hrct chest. * respiratory rate \> 30/ min and not responding to non-rebreather masks. * covid-related pneumonia requiring non-invasive ventilatory support (high-flow nasal cannula, and / or non-invasive ventilation and / or cpap) exclusion criteria: * age \< 18 years * patients who refuse to participate in the study * severe respiratory failure requiring invasive ventilatory support * indication of immediate tracheal intubation * significant acute progressive circulatory insufficiency * impaired conscious level * nasal blockade

Keywords: hfnc hvni
the abc planning study: diabetes and cardiovascular risks in primary care

Conditions: Diabetes

Summary: the purpose of this pilot study is to collect preliminary information about the best way to implement an intervention to reduce the risks of heart disease and stroke.

this study has two types of interventions. the clinics and patients are randomly assigned to either a control or intervention group. all clinics have both control and intervention patients. in the clinic intervention, we help doctors monitor patient information about the risk factors of heart disease and stroke. in the patient intervention, we contact patients by phone to discuss these risk factors before their doctor visits.

Eligibility criteria:
inclusion criteria: * patient must be diagnosed with diabetes for at least 12 months. * patient must be with current physician for at least 12 months. * study staff must be able to reach patient by telephone. exclusion criteria: * pregnant women are excluded.

Keywords: patient activation primary care diabetes cardiovascular risk
the use of inflammatory markers to guide therapy in children with severe asthma

Conditions: Asthma

Summary: the purpose of this study is to determine whether using non-invasive measurements of airway inflammation can improve clinical decision making in children with severe asthma compared to conventional management (british thoracic society guidelines)

children with severe asthma pose a management dilemma; it is difficult to reduce their treatment while they are symptomatic, but the plateau of the dose response curve for inhaled corticosteroids (ics) may have been reached. studies in symptomatic adults and asymptomatic children with asthma suggest measuring induced sputum eosinophils allows better asthma management. we will recruit 80 children with severe asthma (treated with at least 500 mcg/day inhaled fluticasone or equivalent). we will see them every three months for a year, and perform sputum induction and measurements of exhaled nitric oxide (eno). half will be randomised to conventional management; half will have a reduction of ics if there are no sputum eosinophils, or (if a sample cannot be produced) eno is normal. the trial endpoint is whether there is a significant reduction in the median dose of ics in the inflammatory markers group, with no increase in total number of asthma exacerbations. this study is also hypothesis generating. we will use our panel of markers (a) to try to improve clinical monitoring; and (b) to determine the molecular mechanisms of relapse of severe asthma.

Eligibility criteria:
inclusion criteria: children \>8 years with severe asthma defined as: taking at least 500mcg fluticasone propionate (or equivalent) per day, plus a long acting beta agonist plus a leukotriene antagonist or previous trial exclusion criteria: children taking steroid sparing agent (cyclosporin, azathioprine, methotrexate) children with other major respiratory diagnoses such as bronchiectasis -

Keywords: asthma pediatrics airway inflammation
vaginal dinoprostone administration prior to intrauterine device insertion

Conditions: IUD Insertion Pain

Summary: to investigate whether vaginal dinoprostone administered before the levonorgestrel-releasing intrauterine system(ius) insertion reduces iud insertion pain and difficulty in insertion in adolescents and young women.

long-acting reversible contraception methods are highly effective methods for reduction of the unplanned pregnancy rate worldwide. the intrauterine device is a single procedure that provides reliable, effective and long term contraception for many women. however, the insertion procedure can be associated with a troublesome degree of pain that prevent some women from choosing its use. different interventions have been described to decrease pain perception during intrauterine device insertion with no agreement on an effective one.

Eligibility criteria:
inclusion criteria: * nulliparous adolescent and young women requesting levonorgestrel-releasing intrauterine device exclusion criteria: * pregnancy and contraindication or allergy to dinoprostone or contraindication to iud insertion, chronic pelvic pain,pelvic inflammatory disease,analgesic intake 24 hours prior to iud insertion.
premiloc trial to prevent bronchopulmonary dysplasia in very preterm neonates

Conditions: Bronchopulmonary Dysplasia

Summary: there is increasing evidence linking a fetal and early neonatal systemic inflammatory response syndrome to the subsequent development of bronchopulmonary dysplasia (bpd) and white matter injury (wmi) in very preterm infants. babies with evidence of adrenal insufficiency early in life may not be able to control the inflammatory response and are thereby more likely to develop bpd than babies who do not show such evidence of inflammation. we designed a randomized controlled trial to test the hypothesis whether very preterm babies at high-risk of bpd, treated with low doses of hc during the first 10 days of life, are more likely to survive without bpd at 36 weeks of post-menstrual age (pma), compared to babies treated with placebo.

individual patients and study procedures. entry criteria: gestational age between 24 weeks and 27 weeks + 6 days, babies born to mother with either clinical chorioamnionitis, preterm and prelabor rupture of the membranes (pprom), or preterm labor, written informed consent obtained before inclusion and randomization. exclusion criteria: babies born with birth weight below the 3th percentile, pprom before 22 weeks, major fetal anomaly or congenital malformation, mother refusal or inability to provide consent. stratification: stratum a: 24-25 weeks and stratum b: 26-27 weeks. centrally controlled randomization takes place between 12 and 48 hours of age and patients assigned to the hc group are treated with 0,5 mg/kg hc intravenously twice a day for seven days and once a day for the next three days. ibuprofen is only given to babies with persistent ductus arteriosis (pda) echocardiographically confirmed at 24 hours of age or older. outcome variables. the primary outcome is a dichotomous variable: survival without bpd at 36 weeks pma. a consistent physiologic definition of bpd will be used by all participating centres (walsh mc, pediatrics 2004;114:1305-11). secondary outcome variables include features of wmi on mri performed at 40 weeks pma and neurodevelopmental outcome at 2-year of corrected age. other outcome variables include death before discharge, bpd at 28 days and 36 weeks, duration of mechanical ventilation and o2 supplementation, need for vasopressors, use of open-labeled postnatal steroids (hc or dexamethasone), confirmed or suspected early and late onset sepsis, pda, gastrointestinal perforation, nec, rop, ivh, biological markers of the neonatal inflammatory response syndrome.

Eligibility criteria:
inclusion criteria: * gestational age between 24 weeks and 27 weeks + 6 days * babies born to mother with either clinical chorioamnionitis, preterm and prelabor rupture of the membranes (pprom), or preterm labor * written informed consent obtained before inclusion and randomization. exclusion criteria: * babies born to mothers with birth weight below the 3th percentile * pprom before 22 weeks * major fetal anomaly or congenital malformation * mother refusal or inability to provide consent.

Keywords: hydrocortisone very low birth weight bronchopulmonary dysplasia prevention cerebral palsy